Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Lupus Nephritis

Lupus Nephritis

Lupus Nephritis: An autoimmune disorder characterized by inflammation of the kidneys, often associated with systemic lupus erythematosus.
It can lead to serious complications if not properly managed.
PubCompare.ai's AI-driven platform can optimize your research by identifying the most effective protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Experience a smarter way to conduct your Lupus Nephritis research and find the best solutions.

Most cited protocols related to «Lupus Nephritis»

1
Validating Lupus Nephritis Identification
We employed inpatient and outpatient billing data from Medicaid patients at Brigham and Women's Hospital in Boston to identify lupus nephritis cases. We identified Medicaid patients seen 2000-2007 with > 2 claims for lupus (ICD9 710.0) and compared four separate ICD9-based strategies: 1: greater than 2 claims for any combination of acute or chronic glomerulonephritis (including lupus glomerulonephritis), acute or chronic renal failure, nephritis or nephrotic syndrome (including lupus nephrotic syndrome), renal failure or proteinuria (ICD-9 codes 580.-586. and 791.0), 2: greater than 2 claims for visit to a nephrologist, 3: either strategy 1 or strategy 2 and 4: both strategy 1 and strategy 2.
Independently and blinded to these results, two board-certified rheumatologists performed medical record reviews to validate lupus and lupus nephritis according to American College of Rheumatology Criteria for Systemic Lupus Erythematosus14 (link), 15 (link). To validate the presence of lupus nephritis, we employed the ACR criteria14 (link), 15 (link) referring to the presence of nephritis (persistent proteinuria > 0.5 gms/day, or > 3+ on urinalysis, or cellular casts), AND/OR biopsy-proven renal disease attributed to lupus and classified as Class-III-IV or V (focal or diffuse glomerulonephritis or membranous nephropathy) according to the World Health Organization classification16 (link) for subjects identified by each algorithm. We calculated the positive predictive value (PPV) for each strategy. PPV is calculated as the number with confirmed lupus nephritis divided by the total number subjects within that strategy.
Chibnik L.B., Massarotti E, & Costenbader K.H. (2010). Identification and Validation of Lupus Nephritis Cases Using Administrative Data. Lupus, 19(6), 741-743.
Publication 2010
Biopsy CD3EAP protein, human Cells Chronic Kidney Diseases Glomerulonephritis Inpatient Kidney Diseases Kidney Failure Lupus Erythematosus, Systemic Lupus Nephritis Lupus Vulgaris Membranous Glomerulonephritis Nephritis Nephrologists Nephrotic Syndrome Outpatients Patients Rheumatologist Urinalysis Vision
2
SLE Classification Criteria Development
Using a methodological approach based on measurement science the criteria were developed in four phases (10 (link)): 1) criteria generation, 2) criteria reduction, 3) criteria definition and weighting and 4) refinement and validation (Figure 1). The whole initiative was overseen by a 12-member steering committee (MA, KHC, DD, MM, RR-G, JSS, DW, DB, DK, DJ, TD and SRJ) nominated by EULAR and the ACR in equal numbers, based on SLE and/or methodological experience and previous involvement in international projects.
The current project, jointly supported by the European League Against Rheumatism (EULAR) and the ACR, was originally based on two key concepts. One, we hypothesized that the presence of ANA would be better employed as an entry criterion than as a classification criterion (10 (link)). Such an approach was thought to reflect underlying SLE pathogenesis, and take into account ANA test characteristics of high sensitivity and limited specificity. Two, we expected individual criteria would not be of equal utility (weight) for the classification of SLE (11 (link)), for example mucosal ulcers vs. biopsy-proven lupus nephritis. Accordingly, the validity of using positive ANA as an entry criterion was explicitly addressed in phase 1 of the current activity (12 (link)). Likewise, methodologic strategies to develop weighted criteria were used.
Aringer M., Costenbader K.H., Daikh D.I., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D., Kamen D.L., Jayne D., Cervera R., Costedoat-Chalumeau N., Diamond B., Gladman D.D., Hahn B.H., Hiepe F., Jacobsen S., Khanna D., Lerstrøm K., Massarotti E., McCune W.J., Ruiz-Irastorza G., Sanchez-Guerrero J., Schneider M., Urowitz M.B., Bertsias G., Hoyer B.F., Leuchten N., Tani C., Tedeschi S.K., Touma Z., Schmajuk G., Anic B., Assan F., Chan D.T., Clarke A.E., Crow M.K., Czirják L., Doria A., Graninger W.B., Halda-Kiss B., Hasni S., Izmirly P., Jung M., Kumánovics G., Mariette X., Padjen I., Pego-Reigosa J.M., Romero-Díaz J., Fernández I.R., Seror R., Stummvoll G., Tanaka Y., Tektonidou M.G., Vasconcelos C., Vital E.M., Wallace D.J., Yavuz S., Meroni P.L., Fritzler M.J., Naden R.P., Dörner T, & Johnson S.R. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.), 71(9), 1400-1412.
Publication 2019
Biopsy Collagen Diseases Committee Members Europeans Hypersensitivity Lupus Nephritis Mucous Membrane pathogenesis Ulcer
3
Defining Lupus Nephritis Diagnostic Criteria
For the purpose of these recommendations, lupus nephritis is defined as clinical and laboratory manifestations that meet ACR criteria (persistent proteinuria > 0.5 g per day or greater than 3+ by dipstick, and/or cellular casts including red cell, hemoglobin, granular, tubular or mixed) [12 (link)]. A review of the ACR criteria has recommended that a spot urine creatinine/protein ratio >0.5 can be substituted for the 24 hour protein measurement, and “active urinary sediment” (>5 RBC/hpf, >5 WBC/hpf in the absence of infection, or cellular casts limited to RBC or WBC casts) can be substituted for cellular casts [1 (link)]. An additional, perhaps optimal, criterion is a renal biopsy demonstrating immune complex-mediated glomerulonephritis compatible with lupus nephritis [1 (link)]. Finally, for the purpose of implementing these recommendations, the Core Executive Panel felt that a diagnosis of lupus nephritis should also be considered valid if based on the opinion of a rheumatologist or nephrologist.
Hahn B.H., McMahon M., Wilkinson A., Wallace W.D., Daikh D.I., FitzGerald J., Karpouzas G., Merrill J.T., Wallace D.J., Yazdany J., Ramsey-Goldman R., Singh K., Khalighi M., Choi S., Gogia M., Kafaja S., Kamgar M., Lau C., Martin W.J., Parikh S., Peng J., Rastogi A., Chen W, & Grossman J.M. (2012). American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis. Arthritis care & research, 64(6), 797-808.
Publication 2012
Biopsy CD3EAP protein, human Cells Complex, Immune Creatinine Diagnosis Feelings Glomerulonephritis Hemoglobin Infection Kidney Lupus Nephritis Nephrologists Proteins Rheumatologist Urine
4
Identifying Lupus Nephritis in SLE Patients
We defined individuals with SLE as having ≥ 3 International Classification of Diseases, ninth revision (ICD-9) codes for SLE (710.0), each at least 30 days apart, from hospital discharge diagnoses or physician visit claims. We required three billing codes to eliminate “rule-out” SLE cases. Among individuals with SLE, we identified those with lupus nephritis (LN), defined as having ≥ 2 ICD-9 hospital discharge diagnoses or physician billing claims for nephritis, proteinuria and/or renal failure, on or after the SLE diagnosis, and at least 30 days apart. This algorithm has been demonstrated to have a positive predictive value of 80 percent for the identification of adults with LN in a Medicaid population (20 (link)). We also performed a sensitivity analysis for LN that used >2 SLE claims with the aforementioned >2 LN-related claims.
Feldman C.H., Hiraki L.T., Liu J., Fischer M.A., Solomon D.H., Alarcón G.S., Winkelmayer W.C, & Costenbader K.H. (2013). Epidemiology and Sociodemographics of Systemic Lupus Erythematosus and Lupus Nephritis among U.S. Adults with Medicaid Coverage, 2000–2004. Arthritis and rheumatism, 65(3), 753-763.
Publication 2013
Adult Diagnosis Hypersensitivity Kidney Failure Lupus Nephritis Nephritis Patient Discharge Physicians
5
Belimumab Efficacy in SLE Patients
The evidence base for the SRI evaluation came from a phase II dose-ranging RCT evaluating the safety, tolerability, biologic activity, and efficacy of belimumab combined with SOC in 449 SLE patients who had SELENA-SLEDAI scores of ≥4 at baseline (32 ). Patients with a diagnosis of SLE by ACR criteria (37 (link)) and a history of measurable autoantibodies who were on a stable SOC regimen (2 (link)) for at least 30 days prior to screening were included; patients with active lupus nephritis or central nervous system disease were excluded. Concurrent corticosteroid and immunosuppressive agents could be changed throughout the protocol as clinically indicated. All patients gave informed consent for the study, and there was an independent Data Safety Monitoring Committee (32 ).
Furie R.A., Petri M.A., Wallace D.J., Ginzler E.M., Merrill J.T., Stohl W., Chatham W.W., Strand V., Weinstein A., Chevrier M.R., Zhong J, & Freimuth W.W. (2009). Novel Evidence-Based Systemic Lupus Erythematosus Responder Index. Arthritis and rheumatism, 61(9), 1143-1151.
Publication 2009
Adrenal Cortex Hormones Autoantibodies belimumab Biopharmaceuticals Central Nervous System Diseases Diagnosis Immunosuppressive Agents Lupus Nephritis Patients Safety Treatment Protocols

Most recents protocols related to «Lupus Nephritis»

1
Lupus Nephritis Autoantibody Profiling
Not available on PMC !

Example 11

The autoantibody profiles of SLE patients with lupus nephritis were compared with those of SLE patients without lupus nephritis. Following univariate statistical evaluation, a threshold value of p<0.05 and a 1.5 times modified reactivity compared with the control group were applied. 85 antigens met these criteria and are detailed in Table 2.

FIG. 7 shows the volcano plot of the sera compared with selected lupus nephritis antigens.

Group 2 in Table 2 contains 30 additional and important antigens which can be used for the generation of lupus nephritis biomarker panels.

An L1-penalised logistic regression model with five-fold cross validation and twenty times repetition was computed for the selection of the best candidates. The antigens selected most frequently in this model computation with a frequency of more than 50% constituted the best candidates for the diagnosis of lupus nephritis.

FIG. 8 shows the frequency distribution of the lupus nephritis antigens.

Group 5 comprises further statistically significant antigens suitable for the diagnosis of lupus nephritis.

US11860162B2. Marker sequences for diagnosing and stratifying SLE patients (2024-01-02). Oncimmune Germany GmbH [DE]. Inventors: Angelika Luking [DE], Peter Schulz-Knappe [DE], Carmen Theek [DE], Petra Budde [DE], Anna Telaar [DE].
Full text: Click here
Patent 2024
Antigens Autoantibodies Biological Markers Diagnosis Lupus Nephritis Patients Serum
2
Antibodies in Inflammatory Neuropathies and Membranous Nephropathy
From January 2015 to August 2019 we prospectively recruited patients attending the peripheral nerve clinic in the John Radcliffe Hospital (Oxford, UK) with either confirmed or suspected inflammatory neuropathy to an observational study (Research Ethics Committee approval number 14/SC/0280). These patients provided informed written consent. Serum samples from these patients, and patients with suspected inflammatory neuropathies, received by our laboratory for diagnostic testing between August 2017 and August 2019. were screened for antibodies against paranodal (CNTN1, contactin-associated protein 1—Caspr1, neurofascin 155—NF155) and nodal (NF140/186) antigens.
To investigate whether CNTN1 antibodies might be more widely associated with nephrotic syndrome caused by idiopathic MGN itself, we examined 295 serum samples from patients with idiopathic membranous nephropathy, collected as part of the MRC Glomerulonephritis bank [14 (link)].
Serum samples from 70 patients with other antibody-mediated CNS neurological disorders, 20 with multiple sclerosis, 120 individuals without neurological disease, and 46 patients with lupus nephritis, including pure class V membranous lupus nephritis, were also obtained as controls (S1 Fig).
Information that could identify individual participants was stored confidentially and only accessible at the time of data collection to treating physicians, or those with necessary ethical approval and Good Clinical Practice (GCP) training. Data was subsequently de-identified.
Fehmi J., Davies A.J., Antonelou M., Keddie S., Pikkupeura S., Querol L., Delmont E., Cortese A., Franciotta D., Persson S., Barratt J., Pepper R., Farinha F., Rahman A., Canetti D., Gilbertson J.A., Rendell N.B., Radunovic A., Minton T., Fuller G., Murphy S.M., Carr A.S., Reilly M.R., Eftimov F., Wieske L., Teunissen C.E., Roberts I.S., Ashman N., Salama A.D, & Rinaldi S. (2023). Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis. PLOS ONE, 18(3), e0281156.
Full text: Click here
Publication 2023
Antibodies Antigens CNTNAP1 protein, human Ethics Committees, Research Glomerulonephritis Idiopathic Membranous Glomerulonephritis Immunoglobulins Inflammation Lupus Nephritis Multiple Sclerosis Nephrotic Syndrome Nervous System Disorder Patients Peripheral Nerves Physicians Serum Tissue, Membrane
3
Demographic and Complication Factors in CKD
Demographic characteristics and complications were recorded, including age, sex, body mass index (BMI), education level, dialysis duration, systolic blood pressure, diastolic blood pressure, pulse pressure, smoking, diabetes mellitus, hypertension, primary kidney disease, and history of CVD. Education level was recorded as the highest school level for which a diploma was obtained: primary school or below, middle school, high school and beyond. Primary kidney disease includes chronic glomerulonephritis, diabetic nephropathy, and others (such as IgA nephropathy, nephrotic syndrome, lupus nephritis, Sjogren's syndrome, and ANCA-associated vasculitis). CVD information was obtained from medical history reviews, and CVD was recorded if any of the following conditions were present: angina pectoris, grade III or IV congestive heart failure (as classified based on the guidelines of the New York Heart Association), transient ischemic attack, myocardial infarction, and cerebrovascular accident.
Zhu X., Jing R., Li X., Zhang W., Tang Y, & Liu T. (2023). Left ventricular hypertrophy, carotid atherosclerosis, and cognitive impairment in peritoneal dialysis patients. BMC Cardiovascular Disorders, 23, 127.
Full text: Click here
Publication 2023
Angina Pectoris Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Cerebrovascular Accident Congestive Heart Failure Diabetes Mellitus Diabetic Nephropathy Dialysis Glomerulonephritis Heart High Blood Pressures IGA Glomerulonephritis Index, Body Mass Kidney Diseases Lupus Nephritis Myocardial Infarction Nephrotic Syndrome Pressure, Diastolic Pulse Pressure Sjogren's Syndrome Systolic Pressure Transient Ischemic Attack
4
Atherosclerosis Risk in Systemic Lupus
All study participants underwent a baseline vascular ultrasound assessment for the detection of atherosclerotic plaques in the carotid and femoral arteries. The participants were re-evaluated by vascular ultrasound approximately 3 years after the baseline visit. The following baseline characteristics were recorded at the time of baseline and the 3-year follow-up vascular ultrasound: age, disease-related features (disease duration, disease activity assessed by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), disease damage assessed by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI), antinuclear and anti-dsDNA antibodies, C3 and C4 levels, antiphospholipid antibodies including anticardiolipin and anti-β2GPI antibodies and lupus anticoagulant, which were measured and considered positive according to the laboratory classification criteria for APS,24 (link) lupus nephritis and chronic kidney disease (defined as the presence of glomerular filtration rate <60 mL/min), and medications: immunosuppressives, glucocorticoids use and their cumulative dose at the end of follow-up and during the 3-year follow-up period, while hydroxychloroquine, antihypertensives, statins and antiplatelets were recorded at baseline, at the end of follow-up, and during the follow-up period (reported as use over the 75% and 100% of time between the baseline and last follow-up visit). CVR factors included history of smoking (current or ever, pack-years), arterial hypertension (defined as use of antihypertensive treatment or blood pressure higher than 139/89 mm Hg as average of three sequential readings with 1 min interval in the supine position after at least 10 min of rest), hyperlipidaemia (defined as use of lipid-lowering medication and/or total cholesterol ≥240 mg/dL and/or low-density lipoprotein ≥130 mg/dL and/or triglycerides ≥160 mg/dL), obesity (body mass index ≥30 kg/m2) and family history of coronary artery disease.
Panopoulos S., Drosos G.C., Konstantonis G., Sfikakis P.P, & Tektonidou M.G. (2023). Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE. Lupus Science & Medicine, 10(1), e000864.
Publication 2023
Anti-Antibodies Anti-dsDNA antibody Antihypertensive Agents Antiphospholipid Antibodies beta 2-Glycoprotein I Blood Pressure Blood Vessel Carotid Arteries Cholesterol Chronic Kidney Diseases Coronary Arteriosclerosis Femoral Artery Glomerular Filtration Rate Glucocorticoids High Blood Pressures Hydroxychloroquine Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemia Immunosuppressive Agents Index, Body Mass Lipids Low-Density Lipoproteins Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic Lupus Nephritis Lupus Vulgaris Obesity Pharmaceutical Preparations Plaque, Atherosclerotic Triglycerides Ultrasonography
5
Prognosis of Hypertension in Primary FSGS
The data of 118 children with primary focal segmental glomerulosclerosis admitted to the Nursing Department of West China Second Hospital from January 2012 to January 2017 were retrospectively collected. The children were divided into a hypertension group (n=48) and a control group (n=70) according to whether they had hypertension, and were followed up for 5 years to compare the difference in prognosis between the two groups. The inclusion criteria were as follows: (I) primary focal segmental glomerulosclerosis diagnosed by renal biopsy; (II) aged 3–17 years; and (III) complete clinical medical records. The exclusion criteria were as follows: (I) lost to follow-up; (II) secondary infection; (III) malignant tumor; (IV) solitary kidney; (V) diabetes nephropathy, immunoglobulin A nephropathy, membranous nephropathy, lupus nephritis, purpura nephritis, and other nephropathies; (VI) secondary focal segmental glomerulosclerosis; and (VII) cases in which end-stage renal disease had been diagnosed. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of the Nursing Department of West China Second Hospital (No. 2022KY-0098), and the requirement for the patients’ written informed consent for this retrospective clinical study was waived.
Huang L, & Peng W. (2023). Effect of hypertension on the long-term prognosis of children with primary focal segmental glomerulosclerosis-a retrospective cohort study. Translational Pediatrics, 12(2), 155-161.
Publication 2023
Biopsy Child Diabetic Nephropathy Ethics Committees, Clinical Glomerulosclerosis, Focal High Blood Pressures IGA Glomerulonephritis Kidney Kidney Diseases Kidney Failure, Chronic Lupus Nephritis Malignant Neoplasms Membranous Glomerulonephritis Nephritis Patients Prognosis Purpura Renal Agenesis, Unilateral Secondary Infections

Top products related to «Lupus Nephritis»

1
Enhanced chemi luminescence (ecl) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Israel, France, Sweden, Italy
ECL (Enhanced Chemiluminescence) is a laboratory instrument used for the detection and quantification of proteins in Western blot analysis. It utilizes a chemiluminescent substrate to generate a light signal proportional to the amount of target protein present in the sample. This technique allows for the sensitive and specific detection of proteins within a complex mixture.
2
Au5421 by Beckman Coulter
Sourced in United States
The AU5421 is a fully automated clinical chemistry analyzer designed for high-throughput testing in clinical laboratories. It features a modular design, a large sample capacity, and can perform a wide range of routine and specialized clinical chemistry assays.
3
Xc 408 esr monitor by Mindray
Sourced in China
The XC-408 ESR Monitor is a medical device designed to measure the erythrocyte sedimentation rate (ESR) in a laboratory setting. It provides an automated and standardized method for determining the sedimentation rate of red blood cells in a patient's blood sample.
4
Rabbit anti oxr1 by Merck Group
Rabbit anti-OXR1 is a primary antibody that specifically recognizes the Orexin Receptor 1 (OXR1) protein. OXR1 is a G protein-coupled receptor that plays a role in the regulation of sleep-wake cycles, appetite, and other physiological processes. This antibody can be used for the detection and analysis of OXR1 in various experimental applications.
5
Anti gpx1 antibody by Abcam
The Anti-GPX1 antibody is a laboratory reagent used to detect and measure the expression of the GPX1 (Glutathione Peroxidase 1) protein. GPX1 is an enzyme that plays a key role in the cellular antioxidant defense system. The antibody can be used in various analytical techniques, such as Western blotting, immunohistochemistry, and ELISA, to study the expression and localization of the GPX1 protein in biological samples.
6
Anti cd74 polyclonal antibodies by R&D Systems
Anti-CD74 polyclonal antibodies are a laboratory tool used for the detection and analysis of CD74 protein expression in various biological samples. CD74 is a protein involved in the regulation of the immune response and is commonly used as a marker in immunological research. These antibodies can be used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to identify and quantify CD74 in cellular and tissue samples.
7
Ripa buffer by Thermo Fisher Scientific
Sourced in United States, Germany, China, Switzerland, Japan, United Kingdom, Italy, Australia, Sweden, Belgium, Canada, Denmark, France, Sao Tome and Principe, Macao, Austria, Morocco, Norway, Israel
RIPA buffer is a commonly used lysis buffer for the extraction and solubilization of proteins from cells and tissues. It contains a mixture of ionic and non-ionic detergents that help disrupt cell membranes and release cellular contents, including proteins. The buffer also includes salts and buffers to maintain the pH and ionic strength of the solution.
8
Fitc labeled goat anti mouse igg by Jackson ImmunoResearch
Sourced in United States, United Kingdom
FITC-labeled goat anti-mouse IgG is a secondary antibody that specifically binds to mouse immunoglobulin G (IgG) antibodies. The FITC (Fluorescein Isothiocyanate) label allows for fluorescent detection of the target mouse IgG.
9
Lsm 510 confocal laser scanning microscope by Zeiss
Sourced in Germany, United States, Japan
The LSM 510 is a confocal laser scanning microscope manufactured by Zeiss. It is designed to capture high-resolution images of samples by scanning them with a focused laser beam and detecting the emitted fluorescence or reflected light. The system utilizes a set of optical components, including lenses, mirrors, and detectors, to create a detailed, three-dimensional representation of the sample.
10
Withdeadend colorimetric apoptosis detection system by Promega
The WithDeadEnd™ Colorimetric Apoptosis Detection System is a laboratory equipment product designed to detect and quantify apoptosis, a form of programmed cell death. The system utilizes colorimetric methods to measure apoptotic cells.

More about "Lupus Nephritis"

Lupus Nephritis is an autoimmune disorder characterized by inflammation of the kidneys, often associated with systemic lupus erythematosus (SLE).
It can lead to serious complications if not properly managed.
Lupus nephritis is a subtype of glomerulonephritis, a group of kidney diseases that affect the glomeruli, the filtration units of the kidneys.
Symptoms of lupus nephritis may include proteinuria, hematuria, hypertension, and edema.
Diagnosis typically involves kidney biopsy, which can determine the severity and class of the disease.
Treatment often includes immunosuppressant medications, such as corticosteroids, mycophenolate mofetil, or cyclophosphamide, to control inflammation and prevent further kidney damage.
Researchers studying lupus nephritis may utilize various techniques and tools, such as the ECL assay for measuring autoantibody levels, the AU5421 biochemistry analyzer for lab tests, the XC-408 ESR Monitor for erythrocyte sedimentation rate, and Rabbit anti-OXR1 and Anti-GPX1 antibodies for oxidative stress markers.
Anti-CD74 polyclonal antibodies can be used to assess immune cell activation, while RIPA buffer and FITC-labeled goat anti-mouse IgG facilitate protein extraction and visualization, respectively.
The LSM 510 confocal laser scanning microscope can be employed for high-resolution imaging of kidney tissue, and the WithDeadEnd™ Colorimetric Apoptosis Detection System can be used to detect and quantify apoptosis, or programmed cell death, in the kidneys.
By leveraging these tools and techniques, researchers can gain a deeper understanding of the underlying mechanisms of lupus nephritis, identify potential biomarkers, and develop more effective treatments to improve the quality of life for patients suffering from this complex and debilitating condition.
PubCompare.ai's AI-driven platform can assist in optimizing this research by identifying the most effective protocols from the literature, preprints, and patents, thereby enhancing reproducibility and accuracy.